Predictors of survival in patients with prostate cancer and spinal metastasis

Drzymalski, Dan; Oh, William K.; Werner, Lillian; Regan, Meredith M.; Kantoff, Philip W.; Tuli, Sagun

doi:10.3171/2010.6.spine10167

Cited by 31 publications

(20 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the median survival of lung cancer with bone metastases is 6-7 months [8]. Recently, a retrospective observational study showed that the median overall survival after diagnosis of prostate cancer with spinal metastases was 24 months with an estimated 1-year overall survival of 73 % [9]. The median survival time after diagnosis of breast cancer with bone metastases was 32 months [10].…”

Section: Prognosismentioning

confidence: 98%

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Jia

2014

Clin Transl Oncol

View full text Add to dashboard Cite

Several cancers tend to metastasize to bone, leading to osteolytic or osteoblastic bone lesions. The respective phenotypes of bone destruction and bone formation vary in clinical features, including incidence, prognosis, skeletal-related events and bone biomarkers. In addition, different molecular mechanisms explain the difference in phenotype. For example, molecules involved in osteolytic bone metastases (represented with breast cancer) include parathyroid hormone-related protein, transforming growth factor-β, while in osteoblastic lesions (represented with prostate cancer), endothelin-1 and morphogenetic proteins, etc. play a more important role in bone formation. It is important for us to understand the differences of bone metastases between two phenotypes to help clinicians to understand the underlying mechanisms, behaviors and therapies in development and currently available for bone metastases.

show abstract

Section: Prognosismentioning

confidence: 98%

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Jia

2014

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

“…This study corroborates previous research findings regarding prognosis after bone metastasis. [10][11][12] As noted by Ibrahim et al, most bone metastasis are secondary to breast, prostate and lung cancer. 5 Generally, the 1-year survival rates observed in the present study are lower than other clinical based studies.…”

mentioning

confidence: 94%

“…7 8 Population-based reports on length of survival after bone metastases from many primary cancer types are lacking. In patients with breast, prostate and renal cancer, the reported median survival ranges from 12 to 33 months for patients with bone metastases, [9][10][11][12][13][14] and survival increases with longer time between primary diagnosis and such metastases. 15 On the other hand, survival is low for patients with primary lung cancer and bone metastases, 1-year survival ranging from 9.5% to 12%.…”

Section: Introductionmentioning

confidence: 99%

“…In a clinical setting, having other synchronous metastases in addition to bone metastasis was associated with impaired prognosis compared with bone metastasis only in patients with primary gynaecological or prostate cancer. 11 18 For other cancer types, this information is not available in a population-based setting. We hypothesise that survival for other cancers will follow the above-mentioned pattern, being better when no synchronous metastases are observed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival after bone metastasis by primary cancer type: a Danish population-based cohort study

et al. 2017

View full text Add to dashboard Cite

ObjectiveIn the 10 most common primary types with bone metastases, we aimed to examine survival, further stratifying on bone metastases only or with additional synchronous metastases.MethodsWe included all patients aged 18 years and older with incident hospital diagnosis of solid cancer between 1994 and 2010, subsequently diagnosed with BM until 2012. We followed patients from date of bone metastasis diagnosis until death, emigration or 31 December 2012, whichever came first. We computed 1-year, 3-year and 5-year survival (%) and the corresponding 95% CIs stratified on primary cancer type. Comparing patients with bone metastasis only and patients with other synchronous metastases, we estimated crude and adjusted HRs and corresponding 95% CI for mortality.ResultsWe included 17 251 patients with bone metastasis. The most common primary cancer types with bone metastasis were prostate (34%), breast (22%) and lung (20%). One-year survival after bone metastasis diagnosis was lowest in patients with lung cancer (10%, 95% CI 9% to 11%) and highest in patients with breast cancer (51%, 50% to 53%). At 5 years of follow-up, only patients with breast cancer had over 10% survival (13%, 11% to 14%). The risk of mortality was increased for the majority of cancer types among patients with bone and synchronous metastases compared with bone only (adjusted relative risk 1.29–1.57), except for cervix, ovarian and bladder cancer.ConclusionsWhile patients with bone metastases after most primary cancers have poor survival, one of ten patients with bone metastasis from breast cancer survived 5 years.

show abstract

“…Despite significant improvements in local and systemic therapies, most deaths from prostate cancer are due to metastasis which resist conventional therapies (2)(3)(4). Therefore, novel therapeutic strategies targeting specific molecular markers are being pursued to allow early detection and cure.…”

Section: Introductionmentioning

confidence: 99%

The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME

Sorrenti¹

2011

Int J Oncol

View full text Add to dashboard Cite

Abstract. Benign prostate hypertrophy (BPH) and prostate cancer (PC) are prostate chronic diseases that require a long period for development from a small lesion to clinical manifestation. PC is the most common cancer in men in Europe and the Americas. Tumor growth and metastasis depend upon the development of neovasculature around the tumor. This process, called angiogenesis, may be regulated by NO, and thus modulation of NO production could play an important role in tumor progression. Recent studies report the involvement of DDAH, an enzyme which metabolizes the endogenous NOS inhibitor ADMA, in the development of tumor vasculature. The aim of the present study was to verify the involvement of the DDAH/ NOS pathway in the progression of prostate cancer. The effect of the NOS inhibitor L-NAME was evaluated in the human prostate cancer cell line LnCap and in BPH-1 cells which represent benign prostatic hypertrophy. Higher DDAH-2, eNOS, iNOS and VEGF expression was found in LnCap cells compared to BPH-1 cells. L-NAME treatment of LnCap cells resulted in a reduction in VEGF, iNOS and eNOS expression. VEGF, iNOS and eNOS inhibition is a promising approach for targeting tumor vasculature and certain NOS inhibitors could potentially serve as experimental agents for treatment of certain chemoresistant tumors, including prostate tumors. Moreover, since in our experimental conditions L-NAME was unable to reduce DDAH activity and expression, it is plausible to hypothesize the development of a targeted polypharmacological approach by developing dual and specific inhibitors of DDAH and NOS to better control NO biosynthesis. IntroductionBenign prostate hypertrophy (BPH) and prostate cancer (PC) are prostate chronic diseases that require a long period for development from a small lesion to clinical manifestation. PC is the second leading cause of death in men of Western world (1) Despite significant improvements in local and systemic therapies, most deaths from prostate cancer are due to metastasis which resist conventional therapies (2-4). Therefore, novel therapeutic strategies targeting specific molecular markers are being pursued to allow early detection and cure.Tumor growth and metastasis depend upon the development of a neovasculature around the tumor (5-9). This process, called angiogenesis, is critical to tumorigenicity and metastasis (10). Similarly to carcinogenesis, angiogenesis is a multistep process, regulated by a balance between stimulatory and inhibitory factors released by the tumor and its microenvironment (7,(11)(12)(13)(14)(15)(16)(17).Angiogenesis facilitates tumor growth through a series of steps including dissociation of endothelial cells (EC) from adjacent perycites, remodelling of extracellular matrix, proliferation and migration of EC and capillary differentiation.Nitric oxide (NO) is a signalling molecule produced by three isoforms of nitric oxide synthases (neuronal NOS, endothelial NOS and inducible NOS); it mediates a variety of actions such as vasodilatation, neurotransmission, host defence a...

show abstract

Predictors of survival in patients with prostate cancer and spinal metastasis

Cited by 31 publications

References 22 publications

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Survival after bone metastasis by primary cancer type: a Danish population-based cohort study

The DDAH/NOS pathway in human prostatic cancer cell lines: Antiangiogenic effect of L-NAME

Contact Info

Product

Resources

About